Insider · CIK 0001492749

Reid Laurence

Reports to the SEC for 4 companies · EMERYVILLE, CA

sec.gov

Transactions

Companies

Filings

CIK

0001492749

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-09	MGXMetagenomi Therapeutics, Inc.P Purchase	Director	PPurchase	+19.9K sh	$1.17	+$23.3K	19,883
2026-09-09	MGXMetagenomi Therapeutics, Inc.P Purchase	Director	PPurchase	+117 sh	$1.18	+$138.06	20,000
2026-06-11	KalVista Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17K sh	—	—	0
2026-06-09	MGXMetagenomi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+17.4K sh	—	—	17,400
2025-09-02	MGXMetagenomi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+42K sh	—	—	42,000
2024-11-23	KalVista Pharmaceuticals, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+17K sh	—	—	17,000
2023-09-25	Decibel Therapeutics, Inc.D Disposition to Issuer	Director, See Remarks	DDisposition to Issuer	−221K sh	—	—	0
2023-09-25	Decibel Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, See Remarks	DDisposition to Issuer	−188K sh	—	—	0
2023-09-25	Decibel Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, See Remarks	DDisposition to Issuer	−72K sh	—	—	0
2023-09-25	Decibel Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, See Remarks	DDisposition to Issuer	−1.07M sh	—	—	0
2023-03-16	Decibel Therapeutics, Inc.A Award	Director, See Remarks	AAward	+195K sh	—	—	220,849
2023-03-16	Decibel Therapeutics, Inc.Stock Options (right to buy)A Award	Director, See Remarks	AAward	+72K sh	—	—	72,000
2022-02-25	Decibel Therapeutics, Inc.Stock Options (right to buy)A Award	Director, See Remarks	AAward	+188K sh	—	—	187,500
2021-09-15	Decibel Therapeutics, Inc.P Purchase	Director, See Remarks	PPurchase	+10K sh	$7.64	+$76.4K	25,849
2014-12-31	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+17K sh	$15.99	+$272K	20,905
2014-12-31	ALNYALNYLAM PHARMACEUTICALS, INC.F Tax Payment	SVP, Chief Business Officer	FTax Payment	−2,802 sh	$97.00	−$272K	18,103
2014-12-31	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	−17K sh	—	—	133,609
2014-12-12	ALNYALNYLAM PHARMACEUTICALS, INC. · Performance Based Stock Option (right to buy)A Award	SVP, Chief Business Officer	AAward	+6,667 sh	—	—	6,667
2014-11-18	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+2,500 sh	$7.10	+$17.8K	6,405
2014-11-18	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+3,861 sh	$9.14	+$35.3K	10,266
2014-11-18	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+3,639 sh	$15.99	+$58.2K	13,905
2014-11-18	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	SVP, Chief Business Officer	SSale	−5,413 sh	$90.30	−$489K	8,492
2014-11-18	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	SVP, Chief Business Officer	SSale	−4,485 sh	$91.08	−$408K	4,007
2014-11-18	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	SVP, Chief Business Officer	SSale	−102 sh	$91.79	−$9,362.437	3,905
2014-11-18	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	−2,500 sh	—	—	12,500
2014-11-18	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	−3,861 sh	—	—	1,728
2014-11-18	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	−3,639 sh	—	—	150,609
2014-08-18	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+2,500 sh	$7.10	+$17.8K	6,405
2014-08-18	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+11K sh	$9.14	+$101K	17,405
2014-08-18	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	SVP, Chief Business Officer	SSale	−6,500 sh	$66.83	−$434K	10,905
2014-08-18	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	SVP, Chief Business Officer	SSale	−7,000 sh	$67.80	−$475K	3,905
2014-08-18	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	−2,500 sh	—	—	15,000
2014-08-18	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	−11K sh	—	—	5,589
2014-02-19	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+10K sh	$7.10	+$71K	20,805
2014-02-19	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+3,500 sh	$15.99	+$56K	24,305
2014-02-19	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	SVP, Chief Business Officer	SSale	−3,079 sh	$78.62	−$242K	21,226
2014-02-19	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	SVP, Chief Business Officer	SSale	−11.5K sh	$80.02	−$917K	9,761
2014-02-19	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	SVP, Chief Business Officer	SSale	−5,456 sh	$80.85	−$441K	4,305
2014-02-19	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	SVP, Chief Business Officer	SSale	−400 sh	$81.45	−$32.6K	3,905
2014-02-19	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	−10K sh	—	—	20,000
2014-02-19	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	−3,500 sh	—	—	154,248
2014-01-23	ALNYALNYLAM PHARMACEUTICALS, INC.F Tax Payment	SVP, Chief Business Officer	FTax Payment	−3,698 sh	$89.49	−$331K	10,805
2013-12-30	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+3,752 sh	$15.99	+$60K	15,433
2013-12-30	ALNYALNYLAM PHARMACEUTICALS, INC.F Tax Payment	SVP, Chief Business Officer	FTax Payment	−930 sh	$64.51	−$60K	14,503
2013-12-30	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	−3,752 sh	—	—	157,748
2013-12-18	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	SVP, Chief Business Officer	AAward	+20K sh	—	—	20,000
2013-11-13	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+13.5K sh	$15.99	+$216K	25,181
2013-11-13	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	SVP, Chief Business Officer	SSale	−13.5K sh	$53.36	−$720K	11,681
2013-11-13	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	−13.5K sh	—	—	161,500
2013-05-28	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	SVP, Chief Business Officer	MExercise/Conversion	+5,000 sh	$7.10	+$35.5K	16,681

Recent filings

Accepted (ET)
Sep 114
Reid Laurence0001193125-26-389550
SEC(opens sec.gov)
Jun 114
Reid Laurence0001193125-26-267272
SEC(opens sec.gov)
Jun 114
Reid Laurence0001492749-26-000002
SEC(opens sec.gov)
Sep 24
Reid Laurence0000950170-25-112535
SEC(opens sec.gov)
Nov 264
Reid Laurence0001415889-24-027736
SEC(opens sec.gov)
Sep 254
Reid Laurence0000899243-23-019490
SEC(opens sec.gov)
Mar 174
Reid Laurence0000899243-23-008873
SEC(opens sec.gov)
Feb 284
Reid Laurence0000899243-22-008086
SEC(opens sec.gov)
Sep 174
Reid Laurence0000899243-21-036500
SEC(opens sec.gov)
Jan 54
ALNYLAM PHARMACEUTICALS, INC.0001553878-15-000001
SEC(opens sec.gov)
Dec 164
ALNYLAM PHARMACEUTICALS, INC.0001553878-14-000028
SEC(opens sec.gov)
Nov 194
ALNYLAM PHARMACEUTICALS, INC.0001553878-14-000022
SEC(opens sec.gov)

Companies

Address

C/O METAGENOMI THERAPEUTICS, INC. 5959 HORTON STREET, 7TH FLOOR

EMERYVILLE, CA, 94608